Where does Catalyst Pharmaceutical's cash flow data come from?

Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	$214.33M+30.8%	$163.89M+130%	$71.41M-14.0%	$83.08M+110%
Depreciation and amortization	$375K-5.5%	$397K+25.6%	$316K+124%	$141K-26.6%
Stock-based compensation	$24.78M+11.4%	$22.25M+56.1%	$14.25M+80.2%	$7.91M+30.2%
Deferred income taxes	——	——	$18.7M+479%	-$4.94M+47.0%
Change in accounts receivable	$66.4M—	——	$43.08M—	——
Change in inventories	$18.09M—	——	$4.74M+536%	-$1.09M-132%
Change in accounts payable	——	$1.8M-83.4%	$10.82M+796%	$1.21M—
Change in accrued liabilities	$24.16M-55.1%	$53.85M+828%	$5.8M-64.6%	$16.39M—
Change in other assets	——	——	——	$807K+120%
Amortization of intangible assets	$37.5M+0.3%	$37.38M+14.8%	$32.57M—	——
Net gains (losses) on investments	$972K-80.8%	$5.08M+67.8%	$3.02M—	$0—
Change in operating lease liabilities	-$401K-8.7%	-$369K-9.2%	-$338K-10.1%	-$307K—
Net cash from operating activities	$208.67M-13.0%	$239.81M+67.0%	$143.6M+23.7%	$116.05M+92.2%
Capital expenditures	$58K-89.6%	$556K+141%	$231K+697%	$29K-97.2%
Purchases of intangible assets	——	——	——	——
Purchases of equity securities	$0—	——	$13.47M—	$0—
Acquired in-process research and development	$0—	——	——	$0—
Net cash from investing activities	-$58K+89.6%	-$556K+99.8%	-$293.5M-3,287%	$9.21M+184%
Repurchases of common stock	$25.3M—	$0—	——	——
Proceeds from issuance of common stock	$0—	——	$0-100%	$9.57M+133%
Taxes paid for net share settlement	$1.77M—	——	$982K—	——
Net cash from financing activities	-$16.99M-112%	$146.64M+1,451%	-$10.86M-741%	$1.69M+121%
Net increase (decrease) in cash	$191.62M-49.6%	$379.92M—	——	$126.95M+208%
Interest paid	$466K-66.6%	$1.4M—	——	$0—
Income taxes paid	$71.99M—	——	$50.46M+558%	$7.67M—
Accretion Of Discount	$350K-58.1%	$835K+163%	-$1.32M-7,665%	-$17K-440%
Amortization of capitalized software and acquired intangible assets	$37.5M+0.3%	$37.38M+14.8%	$32.57M—	——
Depreciation	$375K-5.5%	$397K+25.6%	$316K+124%	$141K-26.6%
Equity Securities, FV-NI, Gain (Loss)	$972K-80.8%	$5.08M+67.8%	$3.02M—	$0—
Accrued expenses and other liabilities	$24.16M-55.1%	$53.85M+828%	$5.8M-64.6%	$16.39M—
Increase (Decrease) in Deferred Income Taxes	——	——	$18.7M+479%	-$4.94M+47.0%
Operating lease liabilities	-$401K-8.7%	-$369K-9.2%	-$338K-10.1%	-$307K—
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	——	$807K+120%
Non Cash Change In Right Of Use Asset	$295K+6.1%	$278K+6.1%	$262K+6.1%	$247K—
Payment Of Liabilities Arising From Asset Acquisition	$4.59M-64.4%	$12.89M+1.7%	$12.67M+1,616%	$738K—
Accrued Milestone Payment Classified As License And Acquired Intangibles Net	$12.5M—	$0—	$0—	——
Increase Decrease In Operating Lease Liability	-$401K-8.7%	-$369K-9.2%	-$338K-10.1%	-$307K—
Free cash flow	$208.61M-12.8%	$239.25M+66.9%	$143.37M—	——
Free cash flow	$208.61M-12.8%	$239.25M+66.9%	$143.37M—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Catalyst Pharmaceutical's cash flow data come from?: Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.